* Olema Pharmaceuticals Inc OLMA.OQ OLMA.O is expected
to show
no change in quarterly revenue when it reports results on May 8
(estimated).
*
* Refinitiv's mean analyst estimate for Olema
Pharmaceuticals Inc
is for a loss of 65 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Olema
Pharmaceuticals Inc is $12, above its last closing price
of $4.10.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.76 -0.77 -0.57 Beat 25.8
Jun. 30 2022 -0.65 -0.64 -0.82 Missed -27.7
Mar. 31 2022 -0.61 -0.57 -0.58 Missed -1.8
Dec. 31 2021 -0.50 -0.49 -0.54 Missed -9.1
Sep. -0.44 -0.46 -0.45 Beat 1.3
30 2021
Jun. 30 2021 -0.38 -0.38 -0.42 Missed -10.5
Mar. 31 2021 -0.28 -0.28 -0.39 Missed -39.3
Dec. 31 2020 -0.18 -0.18 -0.50 Missed -183
This summary was machine generated March 4 at 00:58 GMT. All
figures in US dollars unless otherwise stated